In 2023, the synthetic molecule omaveloxolone (OMAV), an activator of the Nuclear factor Erythroid 2-related Factor 2 (NRF2) pathway, was the first drug to be approved for FRDA treatment [12]. This evidence concerns the gene NFE2L2 and Friedreich ataxia.